In situ etching and co-growth of ultra thin defect-rich oxide layers on porous silicon. Through the construction of nano-sized catalytic interface, the electrolyte addition FEC would decompose to a ...
Cartesian Growth Corp. III Class A ( (CGCT)) just unveiled an announcement. On December 17, 2025, Cartesian Growth Corporation III and Factorial Inc. signed a definitive business combination agreement ...
Cartesian III currently holds approximately $276 million in cash in trust, though this amount is subject to potential redemptions. Assuming no redemptions, the business combination will result in a ...
Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...
FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...
GrapheneOS, a security-focused Android-based operating system, has begun offering a 'security preview release' that applies security patches to Android early. This makes GrapenOS the only ...
In other recent news, Cartesian Therapeutics has been in the spotlight following a series of notable developments. BTIG has raised its price target for Cartesian Therapeutics to $44.00, maintaining a ...
Abstract: This paper presents the modeling and controller design procedures for a Cartesian robot with a T-Bot mechanism. The kinematic and dynamic models of the robot are first derived using ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results